pipeline-prospector-insert
X

Find Novel Oncology Drugs in Discovery in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gene and Cell therapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: RCH Venture Partners

            Deal Size: $700.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 23, 2020

            Details:

            Proceeds from Sana’s financing will be used to advance discovery and development within the company’s core platforms, including gene delivery, immunology, stem cell biology, and gene modification and control.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tumor-infiltrating Treg

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 11, 2020

            Details:

            Under the terms of the agreement, Egle Therapeutics will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lysosome targeting chimeras

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Versant Ventures

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 09, 2020

            Details:

            Proceeds are being used to develop lysosomal targeting chimeras, or LYTACs, as therapeutics for a broad set of currently intractable cell surface targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            First reported E3 ligase beyond Cereblon and VHL shown to support broad targeted protein degradation of multiple targets in vivo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: SBI Investments

            Deal Size: $25.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing May 13, 2020

            Details:

            Modulus will use the proceeds to further its unique small-molecule lead programs in oncology and inflammatory / immune disorders and expand its portfolio of early programs and collaborations including those with its strategic partner, PeptiDream, Inc.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human monoclonal antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Nkarta

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 12, 2020

            Details:

            Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse®, an industry-leading transgenic mouse R&D platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vocimagene amiretrorepvec

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Denovo Biopharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 28, 2020

            Details:

            The acquisition includes Tocagen's retroviral replicating vector platform, investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC and several other development programs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: ARCH Venture Partners

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 27, 2020

            Details:

            The capital would help in clinical advancement of several promising drug targets identified by ROME and may boost launch of multiple discovery programs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TSC-200

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 15, 2020

            Details:

            Under the agreement, TScan will identify and characterize TCRs, and Novartis will have the option to license and develop TCRs for up to three novel targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RNA targeted small molecule

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: $190.0 million Upfront Cash: $190.0 million

            Deal Type: Licensing Agreement April 08, 2020

            Details:

            Arrakis will lead discovery and research activities for each target to a defined point, at which time Roche will have the right to exclusively pursue further preclinical and clinical development.

            PharmaCompass